These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31028726)

  • 1. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas.
    Shafiei S; Kalantari E; Saeednejad Zanjani L; Abolhasani M; Asadi Lari MH; Madjd Z
    Exp Mol Pathol; 2019 Jun; 108():164-172. PubMed ID: 31028726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients.
    Mirzaei A; Tavoosidana G; Modarressi MH; Rad AA; Fazeli MS; Shirkoohi R; Tavakoli-Yaraki M; Madjd Z
    Tumour Biol; 2015 Jun; 36(6):4801-10. PubMed ID: 25631749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.
    Tao H; Tanaka T; Okabe K
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1449-1459. PubMed ID: 28382517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer?
    Mirzaei A; Tavoosidana G; Rad AA; Rezaei F; Tavakoli-Yaraki M; Kadijani AA; Khalili E; Madjd Z
    Tumour Biol; 2016 Feb; 37(2):2405-14. PubMed ID: 26383518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
    Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
    Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
    Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
    World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis.
    Kang XL; He LR; Chen YL; Wang SB
    World J Gastroenterol; 2020 Nov; 26(43):6853-6866. PubMed ID: 33268966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.
    Gao T; Wang M; Xu L; Wen T; Liu J; An G
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2131-40. PubMed ID: 27520310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner.
    Razi S; Sadeghi A; Asadi-Lari Z; Tam KJ; Kalantari E; Madjd Z
    Clin Exp Med; 2021 Feb; 21(1):139-147. PubMed ID: 32965580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
    Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
    Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Essential Role of DCLK1 in Pathogenesis, Diagnostic Procedures and Prognostic Stratification of Colorectal Cancer.
    Gzil A; Szylberg Ł; Jaworski D; Dominiak J; Zarębska I; Grzanka D
    Anticancer Res; 2019 Jun; 39(6):2689-2697. PubMed ID: 31177103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
    Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
    Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic expression of DCLK1-S, a novel DCLK1 isoform, is associated with tumor aggressiveness and worse disease-specific survival in colorectal cancer.
    Kalantari E; Ghods R; Saeednejad Zanjani L; Rahimi M; Eini L; Razmi M; Asadi-Lari M; Madjd Z
    Cancer Biomark; 2022; 33(3):277-289. PubMed ID: 34958000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DCAMKL1 is associated with the malignant status and poor outcome in bladder cancer.
    Zhang S; Zhang G; Guo H
    Tumour Biol; 2017 Jun; 39(6):1010428317703822. PubMed ID: 28621231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
    Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
    Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of doublecortin-like kinase 1 expression in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
    Harada Y; Kazama S; Morikawa T; Emoto S; Murono K; Kaneko M; Sasaki K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Hata K; Nozawa H; Ishihara S; Watanabe T
    APMIS; 2018 Jun; 126(6):486-493. PubMed ID: 29924454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the cancer stem cell marker DCLK1 in patients with lymph node metastases of head and neck cancer.
    Kadletz L; Kenner L; Wiebringhaus R; Jank B; Mayer C; Gurnhofer E; Konrad S; Heiduschka G
    Pathol Res Pract; 2019 Dec; 215(12):152698. PubMed ID: 31706685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of leucine-rich repeat-containing G-protein (Lgr5) and its impact on clinicopathological features of colorectal cancer.
    Gzil A; Zarębska I; Jaworski D; Antosik P; Durślewicz J; Maciejewska J; Domanowska E; Skoczylas-Makowska N; Ahmadi N; Grzanka D; Szylberg Ł
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2547-2557. PubMed ID: 32671503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lgr5High/DCLK1High phenotype is more common in early stage and intestinal subtypes of gastric carcinomas.
    Kalantari E; Asadi Lari MH; Roudi R; Korourian A; Madjd Z
    Cancer Biomark; 2017 Dec; 20(4):563-573. PubMed ID: 28946555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.